Ardaman Shergill to Humans
This is a "connection" page, showing publications Ardaman Shergill has written about Humans.
Connection Strength
0.181
-
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer. Oncology (Williston Park). 2022 10 07; 36(10):620-626.
Score: 0.029
-
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer. 2024 Feb 13; 24(1):201.
Score: 0.008
-
ASO Visual Abstract: Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 01; 31(1):657-658.
Score: 0.008
-
Early Integrated Palliative Care Within a Surgical Oncology Clinic. JAMA Netw Open. 2023 Nov 01; 6(11):e2341928.
Score: 0.008
-
ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases. Ann Surg Oncol. 2024 01; 31(1):655-656.
Score: 0.008
-
Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 Jan; 31(1):645-654.
Score: 0.008
-
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
Score: 0.008
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
Score: 0.008
-
Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. J Gastrointest Surg. 2023 11; 27(11):2560-2562.
Score: 0.008
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
Score: 0.008
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
Score: 0.008
-
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023 03 01; 9(3):404-413.
Score: 0.007
-
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
Score: 0.007
-
PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 May; 30(5):3114-3122.
Score: 0.007
-
Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases. J Surg Oncol. 2023 Apr; 127(5):831-840.
Score: 0.007
-
Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. J Gastrointest Surg. 2022 12; 26(12):2591-2594.
Score: 0.007
-
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
Score: 0.007
-
DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
Score: 0.007
-
Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC. Ann Surg Oncol. 2021 Nov; 28(12):6955-6964.
Score: 0.007
-
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1777-1785.
Score: 0.006
-
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
Score: 0.006
-
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):350-7.
Score: 0.005